Anti-Aging Supplement Company’s Suit Lacks Standing, FDA Says

The Food and Drug Administration urged a federal court to dismiss for lack of standing a bioscience company’s lawsuit accusing the agency of improperly approving a new dietary supplement ingredient.

Niagen, which sells a patented form of vitamin B3 as an anti-aging supplement, sued the FDA in February for allowing the sale of a new form of vitamin B3 that it alleges was illegally sold before the agency approved it. Niagen had opted against investing in that derivative of vitamin B3, known as nicotinamide mononucleotide, because the substance was being investigated as a drug and regulations blocked marketing it as ...